Novartis AG bears the distinction of being the first to market with a cell therapy, the CAR-T Kymriah (tisagenlecleucel), which won US Food and Drug Administration approval in August 2017 for acute lymphoblastic leukemia (ALL) in children, followed by diffuse large B-cell lymphoma (DLBCL) for adults the next year. But since then, it has fallen behind the second CAR-T to win approval, Gilead Sciences, Inc.’s Yescarta (axicabtagene ciloleucel). Now, Novartis is hoping to regain a leading role in the cell therapy space with new data in multiple myeloma at the American Society of Clinical Oncology meeting.
Both companies presented data for their CAR-Ts at ASCO in early June, including Gilead presentations on Yescarta and its sister...








